Jason Stibich, MD
Geriatric Medicine · Brandon, FLNPI 1619905882
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 607 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,611 and has fallen 66.3% since, to $880 in 2025. Among geriatric medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 607 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$992
- Pfizer$857
- Lilly USA, LLC$846
- AstraZeneca$792
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$481
- plus $5K from 48 others
What the payments were for
- Food & beverage$10,67299%
- Education$881%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$140
- NURTEC ODT$125
- Ozempic$120
How this compares
$10,759 in reported general payments places this provider in the 95th percentile of 305 geriatric medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 340 | $427,211 |
| JardianceEmpagliflozin | 140 | $158,876 |
| MounjaroTirzepatide | 105 | $137,904 |
| XareltoRivaroxaban | 93 | $104,442 |
| FarxigaDapagliflozin Propanediol | 61 | $75,242 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $73,404 |
| JanuviaSitagliptin Phosphate | 48 | $60,623 |
| RybelsusSemaglutide | 30 | $54,472 |
| OzempicSemaglutide | 47 | $48,513 |
| TrulicityDulaglutide | 22 | $37,419 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $27,914 |
| Repatha SureclickEvolocumab | 18 | $26,157 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $20,974 |
| ProliaDenosumab | 11 | $19,116 |
| LinzessLinaclotide | 17 | $17,101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $857 | $427,211340 claims |
| Boehringer IngelheimJardiance, Glyxambi, Spiriva Respimat | $345 | $185,953170 claims |
| Lilly USA, LLCMounjaro, Trulicity | $846 | $175,324127 claims |
| Johnson & JohnsonXarelto | $413 | $104,44293 claims |
| Novo NordiskRybelsus, Ozempic | $992 | $102,98577 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $353 | $94,378107 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $792 | $88,37480 claims |
| MerckJanuvia | $118 | $60,62348 claims |
| AbbVieLinzess, Synthroid | $1,504 | $21,85999 claims |
| AmgenProlia | $271 | $19,11611 claims |
| Astellas Pharma US IncMyrbetriq | $290 | $15,10412 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $42 | $11,12919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 305 geriatric medicine providers in Florida.
Other geriatric medicine in Brandon
- Malcolm FraserBrooksville$359K
- Andrew ScanameoTallahassee$172K
- Naushira PandyaDavie$145K
- Rosemary LairdViera$64K
- Jonathan AppelbaumMonticello$59K
- John PotomskiMelbourne$31K
- Valeria Baldivieso HurtadoWinter Park$28K
- Kae FerberNaples$18K
- Stuti DangMiami$17K
- Angel HerreraNaples$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.